These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16083835)

  • 1. Secondary central nervous system lymphoma: risk factors and prophylaxis.
    Montoto S; Lister TA
    Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
    Lim HY; Thiel E; Glantz MJ
    Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
    Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
    Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
    Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system-directed preventative therapy in adults with lymphoma.
    McMillan A
    Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
    Mazhar D; Stebbing J; Bower M
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS prophylaxis in lymphoma: who to target and what therapy to use.
    Hill QA; Owen RG
    Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
    Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
    Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
    Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how?
    Korfel A
    Curr Opin Oncol; 2011 Sep; 23(5):436-40. PubMed ID: 21760506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
    Bierman P; Giglio P
    Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
    Cheung CW; Burton C; Smith P; Linch DC; Hoskin PJ; Ardeshna KM
    Br J Haematol; 2005 Oct; 131(2):193-200. PubMed ID: 16197449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin lymphoma of the breast.
    Ganjoo K; Advani R; Mariappan MR; McMillan A; Horning S
    Cancer; 2007 Jul; 110(1):25-30. PubMed ID: 17541937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prevention of secondary CNS lymphoma.
    Nagpal S; Glantz MJ; Recht L
    Semin Neurol; 2010 Jul; 30(3):263-72. PubMed ID: 20577933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
    Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
    Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical and trial design considerations in central nervous system prophylaxis studies.
    Smith JA; Glantz M
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S69-76. PubMed ID: 19660685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
    Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
    Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.